id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-3101-0018,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Draft Guidance for Industry; Availability,Other,Guidance,2022-12-05T05:00:00Z,2022,12,2022-12-05T05:00:00Z,2023-03-07T04:59:59Z,2025-06-16T18:00:48Z,,0,0,090000648551989c
FDA-2017-D-3101-0017,FDA,FDA-2017-D-3101,Abbreviated New Drug Applications: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-05T05:00:00Z,2022,12,2022-12-05T05:00:00Z,,2022-12-05T13:29:25Z,2022-26412,0,0,09000064855196fa